BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BGNE BeiGene

Post-Market Trading 12-31 17:36:55 EST

184.71

+0.90

+0.49%

盘后184.71

+0.000.00%

16:00 EST

High187.42	Low183.91	Vol331.61K
Open184.00	D1 Closing183.81	Amplitude1.91%
Mkt Cap19.67B	Tradable Cap11.80B	Total Shares106.47M
T/O61.42M	T/O Rate0.52%	Tradable Shares63.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"BeiGene","latestPrice":184.71,"timestamp":1735678800000,"preClose":183.81,"halted":0,"volume":331608,"hourTrading":{"tag":"盘后","latestPrice":184.71,"preClose":184.71,"latestTime":"16:00 EST","volume":7576,"amount":1399362.96,"timestamp":1735678810432},"delay":0,"floatShares":63889495,"shares":106468226,"eps":-8.186614,"marketStatus":"Post-Market Trading","change":0.9,"latestTime":"12-31 17:36:55 EST","open":184,"high":187.42,"low":183.91,"amount":61423719.6796,"amplitude":0.019096,"askPrice":187.42,"askSize":20,"bidPrice":184.71,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-8.186614,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1735693200000},"marketStatusCode":4,"adr":1,"adrRate":13,"exchange":"NASDAQ","adjPreClose":183.81,"preHourTrading":{"tag":"盘前","latestPrice":183.99,"preClose":183.81,"latestTime":"09:15 EST","volume":692,"amount":126852.75516,"timestamp":1735654511768},"postHourTrading":{"tag":"盘后","latestPrice":184.71,"preClose":184.71,"latestTime":"16:00 EST","volume":7576,"amount":1399362.96,"timestamp":1735678810432},"volumeRatio":1.858533,"impliedVol":0.3978,"impliedVolPercentile":0.3016},"requestUrl":"/m/hq/s/BGNE/tweets","defaultTab":"tweets","newsList":[{"id":"2494633837","title":"BeiGene Secures FDA Approval for Stomach Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2494633837","media":"MT Newswires","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494633837?lang=en_us&edition=fundamental","pubTime":"2024-12-27 22:34","pubTimestamp":1735310090,"startTime":"0","endTime":"0","summary":"BeiGene  said Friday the US Food and Drug Administration approved Tevimbra, its drug to treat a form of stomach cancer, in combination with chemotherapy.Tevimbra, or tislelizumab-jsgr, is approved as a first-line treatment for adults suffering from a certain type of unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, which occurs where the esophagus connects with the stomach, according to the oncology company. The drug is to be used in combination with platinum and fluoropyrimidine-based chemotherapy.The FDA approval is based on results from BeiGene's phase 3 clinical trial to evaluate the efficacy and safety of the drug. The study met its primary endpoint and the product showed a \"statistically significant and clinically meaningful\" overall survival benefit, compared with placebo, with a 20% reduction in the risk of death.Last month, BeiGene disclosed its intention to change its name to BeOne Medicines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-secures-fda-approval-stomach-143450436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"BeiGene Secures FDA Approval for Stomach Cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4535","BK4588","BK4526","BK4504","BGNE","BK4585","BK4139","BK4548"],"gpt_icon":0},{"id":"2494807928","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2494807928","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494807928?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:06","pubTimestamp":1735304789,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively traded Invesco QQQ Trust (QQQ) retreated 0.2% in Friday's premarket activity, as markets turn sluggish","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"48e9a0d5249256980ef300cd13cca795","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".IXIC","RTH","IBB","IVV","EXI","USO","IGV","SPY",".DJI","SDRL","BGNE","PMR","SPY.AU","VDC","IYW","XLY","IYE","IYJ","XLF","XLK","FDN",".SPX","XLV","IPK","FAS","RTH.AU","SOXX","SRFM","WD","EEM","XLP","IYH","QQQ","XRT","GLD","SLV","EQR","UNG","VHT.AU","XLE","VIS","IYK","XLI","IGM","AMPG","XSD","IMKTA","BITO","FAZ"],"gpt_icon":1},{"id":"2494806189","title":"BeiGene Gets FDA Approval for Tevimbra in Stomach-Esophagus Junction Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2494806189","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494806189?lang=en_us&edition=fundamental","pubTime":"2024-12-27 19:30","pubTimestamp":1735299002,"startTime":"0","endTime":"0","summary":"BeiGene  said Friday that its antibody drug Tevimbra has received approval from the US Food and Drug Administration for first-line treatment of stomach-esophagus junction cancer.The approved indication covers a certain type of unresectable or metastatic gastroesophageal junction adenocarcinoma, a rare cancer at the area where the esophagus connects with the stomach, BeiGene said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4139","BK4588","BK1583","06160","BK1161","BK1500","BK4526","LU0588546209.SGD","LU2328871848.SGD","BGNE","BK4535","LU0307460666.USD","LU1969619763.USD","BK1588","BK4585","BK4504","BK4505"],"gpt_icon":0},{"id":"2494972806","title":"BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2494972806","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494972806?lang=en_us&edition=fundamental","pubTime":"2024-12-27 19:29","pubTimestamp":1735298940,"startTime":"0","endTime":"0","summary":"BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer.The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.\"This is the second U.S. approval for Tevimbra this year, underscoring its potential to address critical needs in oncology,\" Chief Medical Officer Mark Lanasa said.BeiGene said the approval was based on results from a global Phase 3 trial that evaluated the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adults with the disease. The company added the study met its primary endpoint and demonstrated a statistically significant and clinically meaningful overall survival benefit.Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresecta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["L","06160","BK4107","BK4588","LU0053666078.USD","BGNE","BK4585"],"gpt_icon":0},{"id":"2494296805","title":"BeiGene announces FDA approval of Tevimbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2494296805","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494296805?lang=en_us&edition=fundamental","pubTime":"2024-12-27 19:05","pubTimestamp":1735297505,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE), a global oncology company that intends to change its name to BeOne Medicines, announced the U.S. FDA has approved Tevimbra in combi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-announces-fda-approval-of-tevimbra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-announces-fda-approval-of-tevimbra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4585","BK4526","BK4588","BK4548","BK4505","BK4504","BGNE","BK4139"],"gpt_icon":0},{"id":"2494030268","title":"TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2494030268","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494030268?lang=en_us&edition=fundamental","pubTime":"2024-12-27 19:00","pubTimestamp":1735297200,"startTime":"0","endTime":"0","summary":"New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers. The pooled safety data in the application included 1,972 patients who received TEVIMBRA monotherapy in two randomized open-label, active-controlled studies  and five open-label, single-arm studies , which enrolled 307 patients with esophageal squamous cell carcinoma and 1,665 patients with advanced or recurrent tumors. The most common Grade 3 or 4 adverse reactions for TEVIMBRA given in combination with chemotherapy were neutropenia, thrombocytopenia, anemia, fatigue, hypokalemia, hyponatremia, pneumonia, decreased appetite, rash, lymphopenia, alanine aminotransferase increased, aspartate aminotransferase increased, diarrhea, pneumonitis, and hepatitis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevimbra-approved-u-first-line-110000528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","PHH","WRD","HSCT","L","BK4097","BK4526","BK4535","LU0053666078.USD","BGNE","BK4505","BK4585","OS","BK4144","BK4504","BK4139","BK4124","BK4588","BK4107","TEN"],"gpt_icon":0},{"id":"2493876040","title":"Exploring Three High Growth Tech Stocks In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2493876040","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493876040?lang=en_us&edition=fundamental","pubTime":"2024-12-24 22:05","pubTimestamp":1735049143,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 2.2%, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In such dynamic conditions, identifying high growth tech stocks involves looking for companies with robust innovation and strong potential to capitalize on emerging trends in technology.Top 10 High Growth Tech Companies In The United States. Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments for patients in the United States, China, Europe, and internationally, with a market cap of $18.75 billion.Operations: BeiGene generates revenue primarily from its pharmaceutical products, amounting to CN23.51 billion. The company is focused on the oncology sector, operating across multiple regions including the United States, China, and Europe.Overview: Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical needs across ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-140543769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU0310799852.SGD","LU1093756168.USD","LU2089283258.USD","BK4568","LU1093756325.SGD","ABBV","IE00BJT1NW94.SGD","LU0158827948.USD","LU0289739699.SGD","BK4532","LU2237443549.SGD","LU1244550577.SGD","LU2237443978.SGD","LU2347655156.SGD","LU2237443382.USD","LU0256863902.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","LU0820561818.USD","LU0965509010.AUD","LU2237443622.USD","LU0256863811.USD","UBCP","LU2468319806.SGD","SG9999015945.SGD","LU1983299246.USD","LU0889565916.HKD","BK4585","GILD","LU0553294199.USD","LU0170899867.USD","LU0708994859.HKD","LU0310800379.SGD","LU1989772923.USD","LU2237443465.HKD","BGNE","LU2089984988.USD","BK4526","LU1066053197.SGD","IE00BVYPNW00.USD","LU0198837287.USD","LU0661504455.SGD","BK4583","LU0058720904.USD","SG9999015986.USD","LU1003077747.HKD","LU1244550221.USD","LU1732800096.USD","LU0965508806.USD"],"gpt_icon":0},{"id":"2493088828","title":"With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns","url":"https://stock-news.laohu8.com/highlight/detail?id=2493088828","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493088828?lang=en_us&edition=fundamental","pubTime":"2024-12-24 18:42","pubTimestamp":1735036955,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in BeiGene implies that they have significant influence over the company's share price. A total of 6 investors have a majority stake in the company with 50% ownership. A look at the shareholders of BeiGene, Ltd.  can tell us which group is most powerful. With 45% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises .Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Let's delve deeper into each type of owner of BeiGene, beginning with the chart below.What Does The Institutional Ownership Tell Us About BeiGene?NasdaqGS:BGNE Earnings and Revenue Growth December 24th 2024. While it makes sense to study institutional ownership data for a company, it also makes sense to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/45-institutional-ownership-beigene-ltd-104235694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","QLD","BK4139","NQmain","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","BEIGF","LU2210149790.SGD","BK4548",".IXIC","NDAQ","TQQQ","USAW.SI","BK4526","BK4535","BK4112","MNQmain","BK4505","PSQ","LU2095319765.USD","TSYW.SI","SQQQ","LU2210150020.SGD","NVIW.SI","USJW.SI","BK4504","IE00B3QW5Z07.USD","QID","BGNE","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2493755627","title":"BeiGene Ltd Updates Nasdaq Ticker Symbol","url":"https://stock-news.laohu8.com/highlight/detail?id=2493755627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493755627?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:39","pubTimestamp":1734953950,"startTime":"0","endTime":"0","summary":"BeiGene Ltd (HK:6160) has released an update. BeiGene Ltd is set to change its Nasdaq ticker symbol from ‘BGNE’ to ‘ONC’ starting January 2, 2025, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigene-ltd-updates-nasdaq-ticker-symbol?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigene-ltd-updates-nasdaq-ticker-symbol?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QLD","NQmain","BK4585","LU2095319765.USD","BK4112","BK4548","BK4504","BGNE","PSQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4505","BK4535","BK4526","NVIW.SI","BK4139","QID","USAW.SI",".IXIC","IE00BGHQF748.EUR","NDAQ","SQQQ","BK4588","IE00B3QW5Z07.USD","MNQmain","TQQQ","TSYW.SI","LU2210150020.SGD","USJW.SI"],"gpt_icon":0},{"id":"2493584287","title":"BeiGene to Change Ticker Symbol to 'ONC', Reflecting Oncology Commitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2493584287","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493584287?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:14","pubTimestamp":1734952452,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) said Monday it will change its ticker symbol to \"ONC,\" effective Jan. 2.BeiGene Co-Founder, Chairman, and Chief Executive John V. Oyler said the change \"reflects our unwavering commitment to leadership in oncology.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","BK4548","06160","BK4504","BK4526","BK4139","BK4588","BK4535","BK4585","BK4505"],"gpt_icon":0},{"id":"2493589087","title":"BRIEF-Beigene's Nasdaq Stock Code To Be Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2493589087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493589087?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:06","pubTimestamp":1734951969,"startTime":"0","endTime":"0","summary":"Dec 23 (Reuters) - Beigene Ltd   :   * SAYS COMPANY'S NASDAQ STOCK CODE WILL BE CHANGED TO ONC FROM BGNE FROM JAN 2    Source text  Further company coverage:    (Reporting by Beijing Newsroom)((yukun.zhang@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGNE","USAW.SI","IE00B3QW5Z07.USD","BK4112","USJW.SI","BK4588","NQmain","LU2210150020.SGD","TSYW.SI","IE00BGHQF748.EUR","NVIW.SI","MNQmain","QID","TQQQ","IE00BKPKM429.USD",".IXIC","QLD","BK4585","NDAQ","LU2095319765.USD","PSQ","IE00B64PRP62.GBP","SQQQ","LU2210149790.SGD"],"gpt_icon":0},{"id":"2493753567","title":"BeiGene to change ticker symbol to ‘ONC’ on January 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493753567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493753567?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:05","pubTimestamp":1734951926,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) intends to change its name to BeOne Medicines Ltd., and will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-to-change-ticker-symbol-to-onc-on-january-2-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-to-change-ticker-symbol-to-onc-on-january-2-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","QLD","BK4139","NQmain","BK4588","BK4548",".IXIC","TQQQ","USAW.SI","BK4526","BK4535","MNQmain","BK4505","PSQ","TSYW.SI","SQQQ","NVIW.SI","USJW.SI","BK4504","QID","BGNE"],"gpt_icon":0},{"id":"2493586757","title":"BeiGene to Change Nasdaq Ticker Symbol to \"ONC\" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2493586757","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493586757?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:00","pubTimestamp":1734951600,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., December 23, 2024----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to \"ONC\" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.\"As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide,\" said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. \"This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7Lzu9_c0m7cQh8uWxkgl4A--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e7945676caf8776fbd1c6ee2fae73115","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7Lzu9_c0m7cQh8uWxkgl4A--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e7945676caf8776fbd1c6ee2fae73115"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-change-nasdaq-ticker-symbol-110000273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","LU0795875169.SGD","BGNE","LU2357305700.SGD","BK4548","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0912757837.SGD","LU2028103732.USD","BK4535","LU2210150020.SGD","HCSG","IE00BKVL7J92.USD","LU1720051017.SGD","LU0106831901.USD","IE00BKPKM429.USD","LU1162221912.USD","BK4581","BK4534","WRD","BK4127","NDAQ","LU2111349929.HKD","BK4504","LU0158827948.USD","LU1363072403.SGD","BK4112","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU2089284900.SGD","BK4588","PHH","IE00B64PRP62.GBP","LU1989772840.SGD","LU2095319765.USD","BK4585","LU0158827781.USD","LU0320765646.SGD","LU2347655156.SGD","LU1732800096.USD","LU1074936037.SGD","LU2089283258.USD","BK4137","LU2271345857.HKD","LU1548497426.USD","LU1989772923.USD","LU2210149790.SGD","LU2023251221.USD","BK4505","LU0006306889.USD"],"gpt_icon":0},{"id":"2492165236","title":"BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2492165236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492165236?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:00","pubTimestamp":1734562817,"startTime":"0","endTime":"0","summary":"BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-gets-fda-orphan-designation-in-waldenstrom-macroglobulinemia-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-gets-fda-orphan-designation-in-waldenstrom-macroglobulinemia-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","BK4588","BK4548","BGNE","BK4535","BK4139","BK4505","BK4585","BK4526"],"gpt_icon":0},{"id":"2492249859","title":"BeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2492249859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492249859?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:36","pubTimestamp":1734500164,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Andrew Berens has maintained their bullish stance on BGNE stock, giving a Buy rating yesterday. Andrew Berens has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-clinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-clinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2492995477","title":"BeiGene’s Strategic Advancements and Promising Pipeline Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2492995477","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492995477?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:15","pubTimestamp":1734441315,"startTime":"0","endTime":"0","summary":"Jefferies analyst Kelly Shi assigned a Buy rating on BeiGene (BGNE – Research Report) today and set a price target of $286.00. Kelly Shi has given ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2492956611","title":"BeiGene (BGNE) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2492956611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492956611?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:15","pubTimestamp":1734437736,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (BGNE – Research Report), with a price target of $260.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-bgne-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-bgne-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4588","COWN","TD","BK4207","BK4535","BK4566","BK4585","BK4504","BK4139","BGNE","BK4505","BK4127","BK4526"],"gpt_icon":0},{"id":"2492995575","title":"BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2492995575","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492995575?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:39","pubTimestamp":1734435591,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-ltds-nasdaqbgne-recent-15-pullback-adds-to-one-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06160","TQQQ","BK1583","BK4548","BK1588","PSQ","BK4112","LU0588546209.SGD","BK4139","LU2328871848.SGD","LU0307460666.USD","QLD",".IXIC","BK4588","QID","BK4505","USJW.SI","BK4504","BK1500","BK4585","SQQQ","TSYW.SI","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","NVIW.SI","BEIGF","IE00BGHQF748.EUR","LU2210150020.SGD","BGNE","LU1969619763.USD","BK4526","MNQmain","BK4535","LU2210149790.SGD","NQmain","LU2095319765.USD","IE00BKPKM429.USD","BK1161","USAW.SI"],"gpt_icon":1},{"id":"2492600575","title":"BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2492600575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492600575?lang=en_us&edition=fundamental","pubTime":"2024-12-17 13:25","pubTimestamp":1734413119,"startTime":"0","endTime":"0","summary":"Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BeiGene (BGNE – Research Report), retaining the price target of $288.00. Reni Be...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-promising-growth-trajectory-and-investment-opportunity-backed-by-strong-product-pipeline-and-robust-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-promising-growth-trajectory-and-investment-opportunity-backed-by-strong-product-pipeline-and-robust-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4535","BK4588","BK4505","BK4526","BK4504","BGNE","BK4548","BK4139"],"gpt_icon":0},{"id":"2491937312","title":"Sector Update: Health Care Stocks Steady Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2491937312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491937312?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:17","pubTimestamp":1734099461,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Friday, with The Health Care Select Sector SPDR Fund  marginally higher and the iShares Biotechnology ETF  inactive.BeiGene  shares were up over 2% after the company said overnight it signed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.Geron  stock was over 1% higher after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.Candel Therapeutics  shares were down past 33% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to a total of 3.3 million shares of its common stock at $5.99 per warrant to raise about $80 million in gross proceeds.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4139","BK4526","XLV","BK4504","GERN","BK4581","BK4505","BK4585","BK4588","BK4539","CADL","IBB","BK4548","BGNE"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0344},{"period":"1month","weight":-0.1451},{"period":"3month","weight":-0.2042},{"period":"6month","weight":0.2421},{"period":"1year","weight":0.0191},{"period":"ytd","weight":0.0191}],"compareEarnings":[{"period":"1week","weight":-0.0109},{"period":"1month","weight":-0.0238},{"period":"3month","weight":0.0345},{"period":"6month","weight":0.0667},{"period":"1year","weight":0.2376},{"period":"ytd","weight":0.2376}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.01513},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.036975}],"exchange":"NASDAQ","name":"BeiGene","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BeiGene,BGNE,BeiGene股票,BeiGene股票老虎,BeiGene股票老虎国际,BeiGene行情,BeiGene股票行情,BeiGene股价,BeiGene股市,BeiGene股票价格,BeiGene股票交易,BeiGene股票购买,BeiGene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction